Loading...

Lyudmila Bazhenova

TitleProfessor of Clinical Medicine
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0987
La Jolla CA 92093
Phone858-822-6189
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators. She believes in a multidisciplinary approach to lung cancer when radiation and surgery plays an important role in patient management. She leads a weekly lung tumor board, so patients can benefit from input of different sub-specialists

    Education and Training
    MD - Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia - 1988-1994
    Resident, Chief Resident and Research Fellowship - Clinical Hospital #38,Nizhny Novgorod State Medical Academy Nizhny Novgorod, Russia - 1994-1995
    Intern/Resident - UCLA VA Medical Center - 1999-2002
    Fellowship - Hematology-Oncology, Scripps-Green Hospital, La Jolla, CA - 2002-2005


    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova L, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 May 16; JCO2017775841. PMID: 29768119.
      View in: PubMed
    2. Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. Oncologist. 2018 May 16. PMID: 29769383.
      View in: PubMed
    3. Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 May 01; 101(1):177-185. PMID: 29487024.
      View in: PubMed
    4. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 Jan; 19(1):101-114. PMID: 29169877.
      View in: PubMed
    5. Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, Masada A, Reitsma DJ, Bazhenova L. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Jan 01; 24(1):43-51. PMID: 29030354.
      View in: PubMed
    6. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova L, Kurzrock R. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. PMID: 28972084.
      View in: PubMed
    7. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 Nov; 16(11):2598-2608. PMID: 28835386.
      View in: PubMed
    8. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. PMID: 28807936.
      View in: PubMed
    9. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. PMID: 28539465.
      View in: PubMed
    10. Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, Krupa R, Louw J, Dugan L, Wang Y, Landers M, Suraneni M, Greene SB, Magaña M, Makani S, Bazhenova L, Dittamore RV, Nieva J. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiol Biomarkers Prev. 2017 Jul; 26(7):1139-1145. PMID: 28446544.
      View in: PubMed
    11. Gettinger SN, Bazhenova L, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. PMID: 27836716.
      View in: PubMed
    12. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1643-1652. PMID: 27751847.
      View in: PubMed
    13. Su HI, Connell MW, Bazhenova L. Ovarian stimulation in young adult cancer survivors on targeted cancer therapies. Fertil Steril. 2016 Nov; 106(6):1475-1478. PMID: 27565250.
      View in: PubMed
    14. Leighl NB, Rizvi NA, de Lima LG, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer. 2017 Jan; 18(1):34-42.e2. PMID: 27686971.
      View in: PubMed
    15. Ettinger DS, Wood DE, Akerley W, Bazhenova L, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 07; 14(7):825-36. PMID: 27407123.
      View in: PubMed
    16. Ettinger DS, Wood DE, Akerley W, Bazhenova L, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar; 14(3):255-64. PMID: 26957612.
      View in: PubMed
    17. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova L, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 04; 15(4):743-52. PMID: 26873727.
      View in: PubMed
    18. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova L, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953; PMCID: PMC4741715.
    19. Klempner SJ, Bazhenova L, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 2015 Sep; 89(3):357-9. PMID: 26187428.
      View in: PubMed
    20. Ettinger DS, Wood DE, Akerley W, Bazhenova L, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5):515-24. PMID: 25964637.
      View in: PubMed
    21. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 2015 Mar 20; 6(8):6029-39. PMID: 25760241; PMCID: PMC4467419.
    22. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015; 14(8):1252-9. PMID: 25695927; PMCID: PMC4614867.
    23. Newton PK, Mason J, Hurt B, Bethel K, Bazhenova L, Nieva J, Kuhn P. Entropy, complexity, and Markov diagrams for random walk cancer models. Sci Rep. 2014 Dec 19; 4:7558. PMID: 25523357; PMCID: PMC4894412.
    24. Ettinger DS, Wood DE, Akerley W, Bazhenova L, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014 Dec; 12(12):1738-61. PMID: 25505215.
      View in: PubMed
    25. Phillips KG, Lee AM, Tormoen GW, Rigg RA, Kolatkar A, Luttgen M, Bethel K, Bazhenova L, Kuhn P, Newton P, McCarty OJ. The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. Am J Physiol Cell Physiol. 2015 Feb 01; 308(3):C229-36. PMID: 25411332; PMCID: PMC4312838.
    26. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36. PMID: 25231400.
      View in: PubMed
    27. Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanawala M, Kolatkar A, Jamali M, Iagaru AH, Kuschner W, Loo BW, Shrager JB, Bethel K, Hoh CK, Bazhenova L, Nieva J, Kuhn P, Gambhir SS. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol. 2014 Aug; 9(8):1111-9. PMID: 25157764; PMCID: PMC4145608.
    28. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. PMID: 24942463.
      View in: PubMed
    29. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova L, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. PMID: 24797821; PMCID: PMC4041669.
    30. Bazhenova L, Newton P, Mason J, Bethel K, Nieva J, Kuhn P. Adrenal metastases in lung cancer: clinical implications of a mathematical model. J Thorac Oncol. 2014 Apr; 9(4):442-6. PMID: 24736064; PMCID: PMC3989547.
    31. Haidar YM, Rahn DA, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis. 2014 Feb; 8(1):3-12. PMID: 24334338.
      View in: PubMed
    32. Sandhu AP, Lau SK, Rahn D, Nath SK, Kim D, Song WY, Gulaya S, Fuster MM, Bazhenova L, Mundt AJ. Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clin Lung Cancer. 2014 Mar; 15(2):131-5. PMID: 24157245.
      View in: PubMed
    33. Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW, Bazhenova L, Nieva J, Gambhir SS, Kuhn P. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PLoS One. 2013; 8(7):e67733. PMID: 23861795.
      View in: PubMed
    34. Randall JM, Bharne AA, Bazhenova L. Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer. J Thorac Dis. 2013 Apr; 5(2):E53-7. PMID: 23585959; PMCID: PMC3621950.
    35. Newton PK, Mason J, Bethel K, Bazhenova L, Nieva J, Norton L, Kuhn P. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res. 2013 May 01; 73(9):2760-9. PMID: 23447576; PMCID: PMC3644026.
    36. Randall JM, Voth R, Burnett E, Bazhenova L, Bardwell WA. Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study. Support Care Cancer. 2013 May; 21(5):1503-7. PMID: 23325092.
      View in: PubMed
    37. Botvin'eva IA, Renge LV, Zorina RM, Bazhenova L, zorina VN. [The proteins of fast phase of inflammation in prognosis of condition of newborn in case of pregnancy complicated by hydramnion and under the risk of intrauterine infection]. Klin Lab Diagn. 2012 Jun; (6):22-5. PMID: 22946221.
      View in: PubMed
    38. Newton PK, Mason J, Bethel K, Bazhenova L, Nieva J, Kuhn P. A stochastic Markov chain model to describe lung cancer growth and metastasis. PLoS One. 2012; 7(4):e34637. PMID: 22558094; PMCID: PMC3338733.
    39. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001. PMID: 22306705; PMCID: PMC3387999.
    40. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, Nieva J, Heuvel Mv, Kuhn P. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol. 2012 Feb; 9(1):016005. PMID: 22307026; PMCID: PMC3387995.
    41. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003. PMID: 22306768; PMCID: PMC3387996.
    42. Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol. 2012 Feb; 9(1):016004. PMID: 22306961; PMCID: PMC3388002.
    43. Ahmad E, Sandhu AP, Fuster MM, Messer K, Pu M, Nobiensky P, Bazhenova L, Seagren S. Hypofractionated radiotherapy as definitive treatment of stage I non-small cell lung cancer in older patients. Am J Clin Oncol. 2011 Jun; 34(3):254-8. PMID: 20562588.
      View in: PubMed
    44. Nath SK, Sandhu AP, Jensen L, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster MM, Bazhenova L, Song WY, Mundt AJ. Frameless image-guided stereotactic body radiation therapy for lung tumors with 4-dimensional computed tomography or 4-dimensional positron emission tomography/ computed tomography. Clin Lung Cancer. 2011 May; 12(3):180-6. PMID: 21663861.
      View in: PubMed
    45. Nath SK, Sandhu AP, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster M, Bazhenova L, Song WY, Mundt AJ. Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiother Oncol. 2011 Apr; 99(1):12-7. PMID: 21429608.
      View in: PubMed
    46. Demoor PA, Matusov Y, Kelly C, Kolan S, Barnachea L, Bazhenova L. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. J Cancer. 2011 Mar 10; 2:153-64. PMID: 21475720; PMCID: PMC3053538.
    47. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6. PMID: 21102269.
      View in: PubMed
    48. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010 Apr 15; 16(8):2450-7. PMID: 20332327.
      View in: PubMed
    49. Sandhu AP, Messer K, Fuster MM, Ahmad E, Pu M, Bazhenova L, Rose M, Seagren S. Definitive radiation therapy for stage I non-small-cell lung carcinoma: institutional experience with contemporary conformal planning. Clin Lung Cancer. 2009 Nov; 10(6):433-7. PMID: 19900862.
      View in: PubMed
    50. Zorina VN, Kozlov IG, Tret'iakova TV, Promzeleva NV, Bazhenova L, Zorina RM, Riabicheva TG, Zorin NA. [Various acute phase reactants in different types of proliferative diseases of the uterine appendages]. Klin Lab Diagn. 2009 Oct; (10):16-9. PMID: 20000108.
      View in: PubMed
    51. Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, Jiang Y, Guo LT, Mizisin AP, Kisilevsky R, Shelton GD, Balch WE, Kelly JW. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci U S A. 2009 Jul 07; 106(27):11125-30. PMID: 19549824; PMCID: PMC2708763.
    52. Markina LA, Zorina VN, Shramko SV, Zorina RM, Arkhipova SV, Bazhenova L. [The serum levels of inflammatory reactants in women with inflammatory diseases of the uterine appendages, who participate in the in-vitro fertilization]. Klin Lab Diagn. 2008 Feb; (2):15-7. PMID: 18354915.
      View in: PubMed
    53. Peterson MR, Piao Z, Bazhenova L, Weidner N, Yi ES. Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. Appl Immunohistochem Mol Morphol. 2007 Sep; 15(3):242-7. PMID: 17721266.
      View in: PubMed
    54. Zorina VN, Predeina EM, Zorina RM, Levchenko VG, Bazhenova L, Zorin NA. [The level of pregnancy-associated alpha2-glycoprotein and the hormonal background during different options of hormonal replacement therapy in the menopausal syndrome]. Klin Lab Diagn. 2007 Jul; (7):24-7. PMID: 17802803.
      View in: PubMed
    55. Bazhenova L, Higginbottom P, Mason J. Intravascular lymphoma: a role for single-agent rituximab. Leuk Lymphoma. 2006 Feb; 47(2):337-41. PMID: 16321868.
      View in: PubMed
    56. Bazhenova L, Du EZ, Bhoyrul S, McCallum J, Saven A. Reactive thrombocytosis associated with a pheochromocytoma. Thromb Haemost. 2005 Aug; 94(2):460-2. PMID: 16113840.
      View in: PubMed
    57. Mena-Duran AV, Togo SH, Bazhenova L, Cervera J, Bethel K, Senent ML, Nieva J, Sanz GF, Sanz MA, Saven A, Mustelin T. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. Br J Haematol. 2005 Jun; 129(6):791-4. PMID: 15953006.
      View in: PubMed